Table 1.

Study characteristics

References	Region	Design	Origin of IVH	Patients		Fibrinolytic	Dose	Quality (NOS/Jadad)	Impact factor
				IVF + EVD	EVD
Akdemir et al. [30]	Middle East	RCT	IPH and SAH	7	9	UK	5000 IU/12 h	2a	2.06
Coplin et al. [34]	N-America	RCS	IPH	22	18	UK	10,000 IU/12 h	6b	5.72
Ducruet et al. [35]	N-America	RCS	IPH	13	17	tPA	1–3 mg/12 h	5b	4.89
Dunatov et al. [12]	Europe	RCS	IPH	48	49	rt-PA	1 mg/12 h	5b	3.09
Findlay et al. [31]	N-America	RCS	SAH	21	9	rt-PA	4 mg/24 h	5b	4.89
Gerner et al. [32]	Europe	M-CS	SAH	14	14	rt-PA	1 mg/8 h	7b	2.75
Hallevi et al. [11]	Middle East	RCS	IPH	18	11	tPA	1–2 mg/24 h	5b	2.47
Hanley et al. [14]	N-America	RCT	IPH	249	251	tPA	1 mg/8 h	5a	44
Huttner et al. [36]	Europe	M-CS	IPH	22	22	rt-PA	2–4 mg/12 h	8b	3.96
King et al. [37]	Asia	RCT	IPH	7	9	UK	25,000 IU/12 h	5a	1.38
Kramer et al. [33]	N-America	RCT	SAH	6	6	tPA	2 mg/12 h	5a	2.75
Litrico et al. [38]	Europe	RCT	SAH	11	8	rt-PA	3 mg/12 h	3a	2.06
Naff et al. [39]	N-America	RCT	IPH	6	5	UK	25,000 IU/12 h	4a	4.89
Naff et al. [25]	N-America	RCT	IPH	26	22	rt-PA	3 mg/12 h	3a	5.72
Rainov and Burkert [26]	Europe	M-CS	IPH	16	5	UK	10,000 IU/12 h	6b	2.06
Todo et al. [27]	Asia	CS	IPH and SAH	6	4	UK	10,000 IU/12 h	4b	3.74
Torres et al. [28]	Europe	RCS	IPH	14	14	UK	10,000 IU/12 h	6b	0.96
Tung et al. [29]	Asia	RCT	IPH	10	11	UK	50,000/12 h	1a	0.96
Varelas et al. [13]	N-America	M-CS	SAH	10	10	tPA	2 mg/12 h	7b	4.89

CS case–control, EVD extraventricular drain, IPH intra-parenchymal hemorrhage, IU international units, IVH intraventricular hemorrhage, IVF intraventricular fibrinolysis, M-CS matched case–control, mg milligram, NA not assessed, NOS Newcastle–Ottawa Outcome Scale, RCS retrospective cohort study, RCT randomized controlled trial, rt-PA recombinant tissue plasminogen activator, SAH subarachnoid hemorrhage, tPA tissue plasminogen activator, UK urokinase

^aScored using Jadad scale, 1–5 points

^bScored using NOS scale, 1–9 points (high quality defined as a score of 4 > = for Jadad, 6 > = for NOS)